Cardiovascular Diseases

In this video, Michael J. Bloch, MD, reviews and discusses a recently published study on the association of menstrual cycle regularity and length with cardiovascular diseases, including how the results...

In a long-term follow-up study, Samar R. El Khoudary, PhD, MPH, BPharm, FAHA, and colleagues investigated how the quantity and quality of cardiovascular fat in women with Alzheimer disease measured during...

In this video, Maura Marcucci, MD, MSc, discusses her study's surprising results, which showed no differences between hypotension-avoidance and hypertension-avoidance strategies for decreasing adverse...

Steven E. Nissen, MD, lead author of the study “Bempedoic Acid And Cardiovascular Outcomes In Statin-Intolerant Patients,” answers questions on the importance of his team’s research on bempedoic acid, how...

In this video, Aldis H. Petriceks, BA, discusses his team's study, which set out to determine the optimal timepoints for assessing orthostatic hypotension in older adults, as well as the association between...

In this video, Matthew C. Tattersall, DO, MS, discusses persistent asthma and its association with carotid plaque burden, which is a strong predictor of atherosclerotic cardiovascular disease events, in the...

In this video, Shaan Khurshid, MD, MPH, talks about his team's study that analyzed a database of nearly 90,000 people and found that concentrated physical activity (1-2 days per week) offers similar heart...

In this article, Michael J Bloch, MD, discusses the usage of RAS-blocking agents, slowing the progression of end-stage renal disease, and reducing cardiovascular events in patients with advanced kidney...

Researchers found that despite eligibility, few adults with type 2 diabetes use GLP-1 receptor agonists and SGLT-2 inhibitors. The study’s lead investigator Shichao Tang, PhD, answers questions about the...

In this article, Michael Bloch, MD, and Evan Bloch discuss findings from the SELECT trial, including the use of the glucagon-like peptide 1 receptor agonist, semaglutide, to reduce the risk of major...